Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$1.16 +3.2%	$1.25	$0.64 ▼ $2.92	$47.07M	-0.75	491,455 shs	28,072 shs
JSPR Jasper Therapeutics	$2.76 -1.4%	$3.58	$2.27 ▼ $26.05	$44.86M	2.77	490,090 shs	194,431 shs
LTRN Lantern Pharma	$4.03 -1.2%	$4.06	$2.55 ▼ $6.12	$43.52M	1.48	138,116 shs	66,098 shs
TXMD TherapeuticsMD	$1.06 -4.5%	$1.14	$0.70 ▼ $2.44	$12.26M	0.51	230,778 shs	16,608 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	-5.94%	-20.57%	+4.07%	-14.52%
JSPR Jasper Therapeutics	0.00%	-5.41%	-2.78%	-52.54%	-87.16%
LTRN Lantern Pharma	0.00%	-10.72%	-14.47%	+26.71%	-0.24%
TXMD TherapeuticsMD	0.00%	-1.33%	0.00%	+2.78%	-41.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRNS Barinthus Biotherapeutics	3.4727 of 5 stars	3.5	5.0	3.8	0.0	1.3
JSPR Jasper Therapeutics	3.0879 of 5 stars	4.3	3.0	1.5	1.7	0.6
LTRN Lantern Pharma	2.8209 of 5 stars	3.5	3.0	3.8	0.8	0.6
TXMD TherapeuticsMD	0.6257 of 5 stars	0.0	3.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	3.00	Buy	$3.00	159.52% Upside
JSPR Jasper Therapeutics	2.60	Moderate Buy	$28.75	941.67% Upside
LTRN Lantern Pharma	3.00	Buy	$25.00	520.35% Upside
TXMD TherapeuticsMD	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TXMD, LTRN, BRNS, and JSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$29.00 ➝ $25.00
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform

(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	3.14	N/A	N/A	$3.23 per share	0.36
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$1.96 per share	N/A
TXMD TherapeuticsMD	$1.76M	6.97	N/A	N/A	$2.37 per share	0.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.73	N/A	N/A	N/A	N/A	-54.70%	-44.75%	11/5/2025 (Estimated)
JSPR Jasper Therapeutics	-$71.27M	-$6.01	N/A	N/A	N/A	N/A	-172.28%	-128.34%	11/6/2025 (Estimated)
LTRN Lantern Pharma	-$20.78M	-$1.78	N/A	N/A	N/A	N/A	-99.89%	-81.58%	11/6/2025 (Estimated)
TXMD TherapeuticsMD	-$2.18M	N/A	0.00	∞	N/A	-17.94%	-2.01%	-1.40%	11/10/2025 (Estimated)

Latest TXMD, LTRN, BRNS, and JSPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.20	-$1.74	-$0.54	-$1.74	N/A	N/A
8/13/2025	Q2 2025	LTRN Lantern Pharma	-$0.53	-$0.40	+$0.13	-$0.40	N/A	N/A
8/12/2025	Q2 2025	TXMD TherapeuticsMD	N/A	$0.05	N/A	$0.05	N/A	$0.95 million
8/7/2025	Q2 2025	BRNS Barinthus Biotherapeutics	-$0.29	-$0.52	-$0.23	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	7.89	7.89
JSPR Jasper Therapeutics	N/A	2.10	2.10
LTRN Lantern Pharma	N/A	3.52	3.52
TXMD TherapeuticsMD	N/A	2.89	2.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
JSPR Jasper Therapeutics	79.85%
LTRN Lantern Pharma	28.62%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	8.00%
JSPR Jasper Therapeutics	4.60%
LTRN Lantern Pharma	8.50%
TXMD TherapeuticsMD	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.72 million	37.46 million	N/A
JSPR Jasper Therapeutics	20	16.25 million	15.51 million	Optionable
LTRN Lantern Pharma	20	10.80 million	9.88 million	Optionable
TXMD TherapeuticsMD	420	11.57 million	11.31 million	Optionable

TXMD, LTRN, BRNS, and JSPR Headlines

Recent News About These Companies

TherapeuticsMD Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

TherapeuticsMD: Q2 Earnings Snapshot

August 12, 2025 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12, 2025 | businesswire.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

TherapeuticsMD Inc. stock rises Monday, still underperforms market

May 12, 2025 | marketwatch.com

TherapeuticsMD Inc. stock outperforms competitors despite losses on the day

April 8, 2025 | marketwatch.com

TherapeuticsMD Announces Full Year 2024 Financial Results

March 27, 2025 | businesswire.com

TherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo Finance

March 26, 2025 | finance.yahoo.com

TherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?

January 7, 2025 | bovnews.comB

TherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True Potential

January 3, 2025 | bovnews.comB

TherapeuticsMD Inc. stock remains steady Friday, still outperforms market

December 27, 2024 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains

November 23, 2024 | marketwatch.com

TherapeuticsMD Shifts Focus with Lower Q3 Losses

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Reports Reduced Losses Amid Strategic Shift

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Announces Third Quarter 2024 Financial Results

November 13, 2024 | finance.yahoo.com

TherapeuticsMD Inc. stock remains steady Monday, underperforms market

November 12, 2024 | marketwatch.com

TherapeuticsMD (NASDAQ:TXMD) Stock, Option Chain

November 6, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD, LTRN, BRNS, and JSPR Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$1.16 +0.04 (+3.21%)

Closing price 03:43 PM Eastern

Extended Trading

$1.16 +0.01 (+0.78%)

As of 04:11 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Jasper Therapeutics NASDAQ:JSPR

$2.76 -0.04 (-1.43%)

Closing price 04:00 PM Eastern

Extended Trading

$2.74 -0.01 (-0.54%)

As of 05:27 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Lantern Pharma NASDAQ:LTRN

$4.03 -0.05 (-1.23%)

Closing price 04:00 PM Eastern

Extended Trading

$4.15 +0.12 (+2.98%)

As of 05:17 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

TherapeuticsMD NASDAQ:TXMD

$1.06 -0.05 (-4.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.10 +0.04 (+3.77%)

As of 05:36 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time